# viDA Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vida-therapeutics

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.vidatherapeutics.com
- Total disclosed funding: $3.6M
- Latest round: Seed (Apr 24, 2013)
- Investors on record: 1

## About

viDA Therapeutics Inc. focuses on developing innovative therapeutics targeting specific serine proteases, particularly granzymes, to address inflammatory and autoimmune conditions.viDA Therapeutics Inc. specializes in creating therapeutics that target serine proteases, specifically granzymes, which play roles in various inflammatory diseases. The company is headquartered in Vancouver, Canada. Founded by Alistair Duncan and David Granville, viDA Therapeutics has raised a total of USD 1.8 mn, with the latest round of funding occurring in July 2013 led by BDC Capital, attracting private investors as well. The company has engaged in a total of 3 deals to date.viDA Therapeutics specializes in developing first-in-class therapeutics that target specific granzymes, focusing on variants Gzm A, B, H, K, and M. Their proprietary inhibitors aim to mitigate the pathological actions of these enzymes, applicable in treating immune-mediated skin diseases, chronic ocular conditions in ophthalmology, and other chronic immune-related disorders. The company's products are designed for pharmaceutical partners and healthcare providers, primarily in North America and Europe, addressing the high burden of inflammatory diseases.viDA Therapeutics generates revenue through strategic collaborations with pharmaceutical companies to advance their therapeutic products. The business model includes B2B transactions through licensing agreements for their proprietary inhibitors, milestone payments, and royalties upon successful commercialization. This revenue structure supports the considerable costs of drug development and regulatory approval, ensuring mutual benefits for viDA and its partners.In July 2013, viDA Therapeutics raised USD 1.8 mn in financing, led by BDC Venture Capital, to advance its product development initiatives. The company plans to design and launch new therapeutic products targeting additional inflammatory conditions and aims to expand into European markets. The recent funding will be allocated to support the clinical development of these innovative therapies, enhancing their market presence and addressing unmet medical needs.

## Funding rounds

- Seed, Apr 24, 2013, $0.8M — BDC Capital
- Seed, Jul 28, 2011, $2.9M — BDC Capital

## Investors

- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Seed